Alastair M. Thompson

The University of Texas MD Anderson Cancer Center

Full Professor(heuristic)

Breast Cancer Treatment Studies · Cancer Research

h-index85

i10-index297

Publications708

Citations39,839

Grants

No NSF/NIH grants on record.

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

Potential Collaborators

Recent Publications

Last 2 years · showing 20 of 75

Early tumor volume reduction by breast DCE MRI predicts pathologic complete response to neoadjuvant therapy in triple negative breast cancer
npj Breast Cancer · 2025-11-20 · 3 citations
Supplementary Table S2 from An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naïve and Longitudinal Samples during Neoadjuvant Chemotherapy
2025-11-03
Supplementary Figure S2 from An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naïve and Longitudinal Samples during Neoadjuvant Chemotherapy
2025-11-03
Supplementary Figure S8 from An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naïve and Longitudinal Samples during Neoadjuvant Chemotherapy
2025-11-03
Supplementary Figure S5 from An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naïve and Longitudinal Samples during Neoadjuvant Chemotherapy
2025-11-03
Supplementary Figure S1 from An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naïve and Longitudinal Samples during Neoadjuvant Chemotherapy
2025-11-03
Supplementary Figure S6 from An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naïve and Longitudinal Samples during Neoadjuvant Chemotherapy
2025-11-03
Supplementary Figure S3 from An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naïve and Longitudinal Samples during Neoadjuvant Chemotherapy
2025-11-03
Supplementary Table S1 from An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naïve and Longitudinal Samples during Neoadjuvant Chemotherapy
2025-11-03
Supplementary Table S4 from An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naïve and Longitudinal Samples during Neoadjuvant Chemotherapy
2025-11-03
Data from An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naïve and Longitudinal Samples during Neoadjuvant Chemotherapy
2025-11-03
Supplementary Figure S4 from An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naïve and Longitudinal Samples during Neoadjuvant Chemotherapy
2025-11-03
Supplementary Figure S12 from An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naïve and Longitudinal Samples during Neoadjuvant Chemotherapy
2025-11-03
Supplementary Figure S11 from An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naïve and Longitudinal Samples during Neoadjuvant Chemotherapy
2025-11-03
Supplementary Figure S7 from An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naïve and Longitudinal Samples during Neoadjuvant Chemotherapy
2025-11-03
Supplementary Table S3 from An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naïve and Longitudinal Samples during Neoadjuvant Chemotherapy
2025-11-03
Supplementary Figure S9 from An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naïve and Longitudinal Samples during Neoadjuvant Chemotherapy
2025-11-03
Supplementary Figure S10 from An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naïve and Longitudinal Samples during Neoadjuvant Chemotherapy
2025-11-03
A core outcome set for locoregional treatment reporting in neoadjuvant systemic breast cancer treatment trials
npj Breast Cancer · 2025-10-28
Imaging- and Tumor Biomarker–Based Multivariable Model for Early Prediction of Pathologic Complete Response to Neoadjuvant Systemic Therapy in Triple-Negative Breast Cancer
JCO Precision Oncology · 2025-10-01 · 2 citations

Open author page on OpenAlex →